"The identification of patients most likely to benefit from targeted therapy is critical to accelerating the drug development and approval process" The biomarkers will be the subject of clinical studies in ovarian cancer and mesothelioma, including a potentially pivotal study of VS-6063 in mesothelioma expected to initiate later this year.
http://eon.businesswire.com/news/eon/20130109005754/en/Verastem-Enters-Biomarker-Agreement-LabCorp-Cancer-Stem
http://eon.businesswire.com/news/eon/20130109005754/en/Verastem-Enters-Biomarker-Agreement-LabCorp-Cancer-Stem
No comments:
Post a Comment